Leisure Capital Management Reduces Stock Position in Pfizer Inc. (NYSE:PFE)

Leisure Capital Management reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,988 shares of the biopharmaceutical company’s stock after selling 556 shares during the quarter. Leisure Capital Management’s holdings in Pfizer were worth $345,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Intact Investment Management Inc. lifted its stake in shares of Pfizer by 30.9% during the 4th quarter. Intact Investment Management Inc. now owns 438,800 shares of the biopharmaceutical company’s stock valued at $12,633,000 after buying an additional 103,600 shares in the last quarter. Addison Advisors LLC lifted its stake in Pfizer by 11.6% in the 4th quarter. Addison Advisors LLC now owns 9,322 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 970 shares in the last quarter. Gilliland Jeter Wealth Management LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $962,000. Headlands Technologies LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $1,184,000. Finally, Citizens Financial Group Inc. RI lifted its stake in Pfizer by 40.7% in the 4th quarter. Citizens Financial Group Inc. RI now owns 145,969 shares of the biopharmaceutical company’s stock worth $4,202,000 after purchasing an additional 42,202 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Finally, Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Trading Up 0.6 %

Pfizer stock traded up $0.14 during trading hours on Friday, reaching $25.40. The stock had a trading volume of 46,526,457 shares, compared to its average volume of 34,120,812. The company has a fifty day simple moving average of $26.96 and a 200-day simple moving average of $28.42. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The stock has a market cap of $143.83 billion, a PE ratio of 70.56, a PEG ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same period last year, the company posted $1.14 EPS. Pfizer’s revenue was down 41.3% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.61%. Pfizer’s dividend payout ratio is presently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.